Lawyers Iliana Djagova

Iliana Djagova

Iliana Djagova

Counsel
lic. iur., LL.M., Attorney at Law

Location

Contact

Direct phone: +41 58 658 56 98
iliana.djagova@walderwyss.com

Curriculum Vitae

Areas of activity: Corporate / M&A Commercial Contracts

Iliana Djagova is a counsel in the Corporate/M&A team of Walder Wyss. She has extensive experience advising on complex domestic and cross-border M&A transactions, growth equity financings and late-stage investments. She regularly acts for strategic and financial investors, including private equity firms, on both the buy-side and sell-side. Iliana Djagova also advises companies and shareholders throughout all stages of their lifecycle, with a particular focus on growth-stage and exit transactions. In addition, she counsels private and listed companies, as well as their shareholders, on corporate governance and general corporate and commercial law matters.

Prior to joining Walder Wyss in 2023, Iliana Djagova spent eight years at another leading Swiss law firm, advising on high-profile M&A and private equity transactions. In 2015/16 she further broadened her international experience at Willkie Farr & Gallagher LLP in New York, USA.

Iliana Djagova studied law at the University of Geneva and Zurich (lic. iur., 2010) and the University of California, Berkeley (LL.M., 2015). She was admitted to the Zurich Bar in 2013 and to the New York Bar in 2018.

Iliana Djagova’s professional languages are German and English. She also speaks Bulgarian and French.

Walder Wyss advised Novo Holdings on the acquisition of Catalent

30 January 2025

SoftwareOne to launch tender offer for all outstanding Crayon shares

19 December 2024

Alentis Therapeutics Raises USD 181.4m in an Oversubscribed Series D Financing to Advance the Clinical Development of Anti-Claudin-1 ADCs in Solid Tumors

12 November 2024

Boehringer Ingelheim acquires veterinary therapeutic vaccines developer Saiba Animal Health

10 September 2024

Swixx Biopharma acquires Biopas to enter Latin America

SOPHiA GENETICS SA closed secured term loan financing

Walder Wyss advised CRISPR Therapeutics (NASDAQ) on USD 280 Million Equity Issuance

16 February 2024

Walder Wyss advised Nasdaq listed Altamira Therapeutics in its sale of majority stake in Altamira Medica

5 December 2023

Other lawyers

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.